Anika Therapeutics (ANIK) Tops Q4 EPS by 28c ; Offers Guidance
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $15.36 +1.19%
EPS Growth %: +115.4%
Financial Fact:
Net income: 0.59
Today's EPS Names:
CRMT, More
EPS Growth %: +115.4%
Financial Fact:
Net income: 0.59
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.05, $0.28 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $43 million versus the consensus estimate of $41.4 million.
GUIDANCE:
Anika Therapeutics sees FY 2024 revenue of $168-173 million, versus the consensus of $179.4 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
- SAS CEO van der Werff emerges as frontrunner for Air Canada top job - Bloomberg
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
